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Abstract: The Finnish Medical Society Duodecim initiated and managed the update of the Finnish national guideline for chronic
obstructive pulmonary disease (COPD). The Finnish COPD guideline was revised to acknowledge the progress in diagnosis and
management of COPD. This Finnish COPD guideline in English language is a part of the original guideline and focuses on the
diagnosis, assessment and pharmacotherapy of stable COPD. It is intended to be used mainly in primary health care but not for-
getting respiratory specialists and other healthcare workers. The new recommendations and statements are based on the best evi-
dence available from the medical literature, other published national guidelines and the GOLD (Global Initiative for Chronic
Obstructive Lung Disease) report. This guideline introduces the diagnostic approach, differential diagnostics towards asthma,
assessment and treatment strategy to control symptoms and to prevent exacerbations. The pharmacotherapy is based on the symp-
toms and a clinical phenotype of the individual patient. The guideline defines three clinically relevant phenotypes including the
low and high exacerbation risk phenotypes and the neglected asthma–COPD overlap syndrome (ACOS). These clinical pheno-
types can help clinicians to identify patients that respond to specific pharmacological interventions. For the low exacerbation risk
phenotype, pharmacotherapy with short-acting b2-agonists (salbutamol, terbutaline) or anticholinergics (ipratropium) or their com-
bination (fenoterol–ipratropium) is recommended in patients with less symptoms. If short-acting bronchodilators are not enough
to control symptoms, a long-acting b2-agonist (formoterol, indacaterol, olodaterol or salmeterol) or a long-acting anticholinergic
(muscarinic receptor antagonists; aclidinium, glycopyrronium, tiotropium, umeclidinium) or their combination is recommended.
For the high exacerbation risk phenotype, pharmacotherapy with a long-acting anticholinergic or a fixed combination of an
inhaled glucocorticoid and a long-acting b2-agonist (budesonide–formoterol, beclomethasone dipropionate–formoterol, fluticasone
propionate–salmeterol or fluticasone furoate–vilanterol) is recommended as a first choice. Other treatment options for this pheno-
type include combination of long-acting bronchodilators given from separate inhalers or as a fixed combination (glycopyrroni-
um–indacaterol or umeclidinium–vilanterol) or a triple combination of an inhaled glucocorticoid, a long-acting b2-agonist and a
long-acting anticholinergic. If the patient has severe-to-very severe COPD (FEV1 < 50% predicted), chronic bronchitis and fre-
quent exacerbations despite long-acting bronchodilators, the pharmacotherapy may include also roflumilast. ACOS is a phenotype
of COPD in which there are features that comply with both asthma and COPD. Patients belonging to this phenotype have usu-
ally been excluded from studies evaluating the effects of drugs both in asthma and in COPD. Thus, evidence-based recommenda-
tion of treatment cannot be given. The treatment should cover both diseases. Generally, the therapy should include at least
inhaled glucocorticoids (beclomethasone dipropionate, budesonide, ciclesonide, fluticasone furoate, fluticasone propionate or mo-
metasone) combined with a long-acting bronchodilator (b2-agonist or anticholinergic or both).
The Finnish Medical Society Duodecim has created a system
for the production of national guidelines on the most impor-
tant diseases. These guidelines provide the basis of evidence-
based treatment of about 100 common health problems and
are based on a rigorous evaluation of evidence and production
of the guidelines in a specific format including formal level of
evidence statements (A–D; see table 1) [1], and this level of
evidence is also referred in the current MiniReview. The major
difference between the current guideline and most other guide-
lines for chronic obstructive pulmonary disease (COPD) is that
the short reviews of the literature presenting the evidence sup-
porting the claim for a certain level of evidence (A–D) are
publicly available [1,2]. These guidelines and statements (in
the Finnish language) are published on the website of the
medical society Duodecim [1,2] and are available to all physi-
cians as well as to the general public in Finland. In addition,
patient versions are occasionally published. During summer
2012, the Finnish Medical Society Duodecim and the Finnish
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Respiratory Society invited members to a group aiming to
update the previous guideline on COPD. The production of
the novel guideline was started in October 2012, and the final
version of the guideline (in Finnish) was accepted and pub-
lished on 13 June 2014 after a long review process [2].
In Finland, the diagnostics and treatment of common respi-
ratory diseases such as asthma and COPD are mainly per-
formed in primary health care by general practitioners, and
only a part of the patients are treated by respiratory specialists.
The Finnish Medical Society Duodecim represents the whole
medical community in Finland, and the society necessitates
that the guideline should serve especially the general practitio-
ners working in primary health care. However, the guideline is
also widely used by respiratory specialists and other healthcare
specialists such as nurses and pharmacists. Thus, the main
requirements for the guideline were that it should be evidence
based, accurate, clear and simple enough to be used in a busy
general practice.
The need to update the guideline for the treatment of COPD
was aroused by the prevalence of COPD in the Finnish
patients and its importance and costs to patients and to the
healthcare system as well as the paradigm shift in the treat-
ment of COPD started by the GOLD (Global Initiative for
Chronic Obstructive Lung Disease) report [3]. This guideline
greatly owes to the international GOLD report [3] as well as
to the innovative guideline for COPD by the Spanish Respira-
tory Society [4]. The present guideline introduces a modified
and hopefully, simplified version of pharmacological treatment
based on the assessment of exacerbation risk presented in the
GOLD report [3] and Spanish guideline [4]. It takes into the
account the neglected phenotype of COPD–asthma as pre-
sented in the Spanish COPD guideline [4,5] or asthma–COPD
overlap syndrome (ACOS) as termed by the recent GINA
report [6]. Asthma and COPD are generally diagnosed, treated
and managed by the same personnel (nurses and general prac-
titioners) in Finland. As there are some crucial differences in
the treatment of these two common diseases, accurate diagno-
sis and clear treatment guidelines are of utmost importance.
Thus, in the preparation of the present guideline, the diagnos-
tic section was co-ordinated with the recently published
asthma guideline as three members served in this group (H.K.,
T.H. and L.L.) who were also involved in the production of
the asthma guideline [7]. Special attention was drawn to the
diagnosis of COPD, differential diagnosis between asthma and
COPD, and the inclusion of the ACOS. In addition, the phar-
macological treatment section was developed to pursue readi-
ness, simplicity and in-depth precision at the same time. This
Finnish COPD guideline in the English language covers only
a part of the original guideline [2,8,9], that is the diagnostics,
comprehensive assessment and pharmacological treatment of
stable COPD. Other sections such as epidemiology, screening,
tobacco cessation, oxygen therapy, ventilatory support, surgi-
cal treatments, pulmonary rehabilitation, management of acute
exacerbations and palliative care can be found in the original
document in Finnish [2,9]. This version of the guideline has
been updated to contain some novel compounds (e.g. umeclid-
inium), fixed combinations of long-acting bronchodilators
(glycopyrronium–indacaterol and umeclidinium–vilanterol) and
fixed combinations of inhaled glucocorticoids (ICS) and long-
acting b2-agonists (beclomethasone dipropionate–formoterol
and fluticasone furoate–vilanterol) not included in the earlier
published Finnish version [2,8] and now available in Finland.
In addition, new relevant literature has been cited.
Diagnostics
The diagnosis of COPD is based on relevant exposure history,
symptoms and airway obstruction that is not fully reversible
(post-bronchodilator forced expiratory volume in one-second/
forced vital capacity < 0.70; FEV1/FVC < 0.70).
Evaluation of predisposing factors.
The following predisposing factors should be assessed in the
diagnostic evaluation: smoking history (in pack-years), current
smoking, passive smoking, occupational exposures, previous
respiratory infections, asthma and respiratory diseases in the
family.
Symptoms.
Typical symptoms of COPD include dyspnoea, chest tight-
ness, wheezing, cough and sputum production [3], but the
diagnosis of COPD cannot be based on symptoms alone, as
some patients are symptom free and similar symptoms can
be caused by other diseases [10]. However, symptoms sug-
gestive of COPD in an individual with exposure to tobacco
or other risk factors should lead to spirometry and other
diagnostic evaluations. In patients with established COPD,
the level of symptoms and the presence of exacerbations
should be assessed as these are used to guide the treatment
Table 1.
Grading of the evidence in the Current Care Guidelines.
Level of evidence Description (verbal expression in the text)
A Strong research-based evidence (multiple, relevant, high-quality studies with homogeneous results – e.g. two or more
randomized, controlled trials or a systematic review with clearly positive results)
B Moderate evidence (e.g. one randomized, controlled trial or multiple adequate studies)
(. . .apparently. . .)
C Limited research-based evidence (e.g. controlled, prospective studies)
(. . .may. . .)
D No evidence (e.g. retrospective studies or the consensus reached in the absence of good-quality evidence)
Adapted from reference [1].
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[3]. COPD is a progressive disease and symptoms tend to
worsen, especially if the patient continues smoking, and
dyspnoea at rest or light exercise, cough, weight loss and fre-
quent exacerbations are often present in advanced severe-to-
very severe COPD [11].
Physical examination.
The diagnosis of COPD cannot be based on clinical signs, but
these can be suggestive of COPD and its degree of severity
[3]. Wheezing may be heard during auscultation of the chest,
but pulmonary sounds can also be normal. Increased respira-
tory rate at rest, the use of accessory respiratory muscles and
signs of right-sided heart failure may be present in severe
COPD.
Pulmonary function testing.
In diagnosing COPD, spirometry should be conducted with
bronchodilation test. COPD can be diagnosed if FEV1/FVC
is <0.70 in a post-bronchodilation spirometry [3]. This
criterion causes some over-diagnosis in elderly people
[12,13] and possibly also in women [14] and under diagno-
sis in individuals younger than 45 years [13], but it is sen-
sitive in detecting COPD clinically assessed by a physician
[15–17]. This criterion is also associated with mortality risk
[18].
Significant reversibility in the bronchodilation test (FEV1
increases at least 12% and 200 ml) can be detected in approxi-
mately 25–50% of individuals with COPD (see Differential
diagnosis below). Classification of severity of airway obstruc-
tion is presented in table 2, but this is only one aspect of the
clinical severity of COPD.
Radiological imaging.
The diagnosis of COPD cannot be based on chest X-ray, but
a chest X-ray should be included in the initial evaluation to
exclude other diseases such as pulmonary cancer, tuberculosis,
pneumonia, heart failure and pleural diseases.
In mild COPD, chest X-ray is almost always normal. In
advanced disease flattening of the diaphragm, long narrow
heart, over-inflation with thinning of blood vessels and
emphysematous bullae can be seen. Computerized tomography
of the chest is not routinely needed, but may be used by spe-
cialists in cases of problematic differential diagnosis to detect
bronchiectasis and in the evaluation for surgical treatment of
COPD [19].
Blood tests and sputum cultures.
There are no specific blood tests to be used in diagnosing
COPD, but some basic tests may be used to rule out other dis-
eases and to assess infections and respiratory failure during
acute exacerbations. Bacterial culture of sputum is not useful
in stable COPD. If COPD is found in a person with exception-
ally young age (<45 years) or with a low smoking history
(<20 pack-years), serum levels of alpha-1-antitrypsin (A1AT)
should be measured to rule out alpha-1-antitrypsin deficiency.
This recommendation may differ from that of other guidelines
[3]. However, screening for A1AT is not recommended for all
patients in Finland, because there is no A1AT replacement
therapy available in Finland. Thus the only relevant therapeu-
tic option is counselling for smoking cessation and the smok-
ing cessation is recommended for all patients with COPD
despite the knowledge of A1AT levels.
Comprehensive evaluation of the patient.
Symptoms, quality of life and the impact of the disease can
be assessed with validated questionnaires such as COPD
Assessment Test (CAT) and modified Medical Research
Council Dyspnea Scale (mMRC) [3]. Six-minute walking test
or ergometry can be used to assess exercise tolerance. The
clinical severity of COPD is assessed based on the degree of
airway obstruction, level of symptoms, exacerbations and
co-morbidities (table 2). Extra-pulmonary manifestations and
co-morbidities such as cardiovascular diseases, metabolic
syndrome, osteoporosis and depression are more prevalent in
individuals with COPD than in non-COPD individuals with
Table 2.
Classification of the severity of obstruction and the clinical severity of chronic obstructive pulmonary disease (COPD).
Severity of obstruction
(assessed after bronchodilation) Clinical severity of COPD
Mild FEV1 ≥ 80% predicted Good quality of life (CAT
 < 10), no frequent exacerbations and FEV1 >50% predicted
Moderate 50% ≤ FEV1 < 80% One of the following:
 FEV1 < 50% predicted
 At least two exacerbations a year or one hospitalization because of COPD
 COPD has a medium impact on life (e.g. CAT ≥ 10 points) or causes poor quality
of life or impaired exercise tolerance
Severe 30% ≤ FEV1 < 50%
Very severe FEV1 < 30% One of the following:
 FEV1 < 30% predicted
 Chronic respiratory failure
 Frequent exacerbations or hospitalizations regardless of treatment to COPD
 COPD has a high or very high impact on life (e.g. CAT ≥ 20 points) or causes
very poor quality of life or exercise tolerance
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similar smoking history. Nutritional status and especially unin-
tended loss of weight should be assessed.
Differential diagnosis.
The most important differential diagnoses include asthma,
chronic bronchitis, lower airway infections (including tubercu-
losis), lung cancer, interstitial lung diseases and heart diseases.
A common diagnostic problem is to distinguish between
asthma and COPD. Although these diseases are often treated
with the same medication, they differ in basic pathology,
aetiology and prognosis. COPD and asthma are often found in
the same individual, and in smoking asthma patients, the cel-
lular components of inflammation may resemble that found in
COPD [3,6]. The differential diagnosis of asthma and COPD
cannot be based on pulmonary function tests alone, but a com-
prehensive approach including smoking history, symptoms,
co-morbidities and family history is needed [3,6].
Bronchodilation test in spirometry cannot reliably distin-
guish between asthma and COPD [3], as asthmatic individuals
do not always present with significant reversibility and
approximately 25–50% of individuals with COPD have signif-
icant reversibility [20–22].
Glucocorticoid therapy test does not always differentiate
between asthma and COPD [23], as a considerable proportion
of individuals with COPD benefit from ICS [24]. On the other
hand, some of the asthmatic individuals are not responsive to
ICS alone [25]. However, if an individual patient clearly bene-
fits from using ICS (i.e. as assessed based on improvement in
lung function or based on a reduction of symptoms or exacer-
bations), it should be continued regardless of the diagnosis
(asthma or COPD). As the response to oral glucocorticoids
does not predict responsiveness to ICS [26,27], the possible
treatment trials should be conducted using ICS at moderate (to
high) doses for (4 to) 8 weeks.
Normalization of lung function by ICS treatment excludes
COPD and strongly supports the diagnosis of asthma. If the
lung function is not significantly changed by ICS treatment,
the diagnosis is more likely COPD than asthma.
Aims of the Treatment of COPD
The goals of the therapy of COPD can be divided into four
major aims:
1 Controlling symptoms and improving the quality of life.
2 Reducing future risk, that is preventing exacerbations.
3 Slowing down the progression of the disease.
4 Reducing mortality.
Multimodal Therapy of COPD
The therapy of COPD includes both non-pharmacological and
pharmacological means. Non-pharmacological treatment
modalities include smoking cessation [28], oxygen therapy,
physical exercise and pulmonary rehabilitation, ventilator sup-
port and surgical therapy. Palliative care in patients nearing
death is discussed in detail in the original document and may
include a trial of opioids for refractory dyspnoea [2,9]. The
risk of physical inactivity in patients with COPD is vastly
increased (A) [29], and the patients should be encouraged to
do physical exercise. Physical activity reduces the risk of mor-
tality and hospitalizations. In contrast, physical inactivity pre-
dicts increased mortality (A) [30,31]. Exercise-based
pulmonary rehabilitation courses should be available for
COPD patients with continued dyspnoea despite the use of
bronchodilators, or when they are physically inactive and suf-
fer from frequent exacerbations, or have exercise intolerance.
These recommendations can be found in detail in the original
document [2,8,9]. Pharmacological therapies include bron-
chodilators, combinations of ICS and long-acting bronchodila-
tors, phosphodiesterase 4 (PDE4) inhibitors or theophylline
and influenza and pneumococcal vaccination.
Vaccination
In the general population, vaccination of persons aged
>65 years against influenza has been found to reduce pneumo-
nia, hospitalization and deaths by 50–68%. A majority of
patients with COPD belong to this age group. Vaccination
against influenza reduces COPD exacerbations (A) [32]. Vac-
cination annually against influenza is recommended for all
patients with COPD.
Pneumococcal vaccination apparently reduces pneumonia of
pneumococcal origin in patients with COPD (B) [33–35].
Pneumococcal vaccination is recommended for patients with
COPD.
Pharmacotherapy of Stable COPD
Principles of regular long-term pharmacotherapy of COPD.
1 There exist two main goals with the current pharmacother-
apy of COPD. They are (1) to control symptoms and (2)
to reduce future risk (i.e. the exacerbations of COPD). The
grounds for the use of any particular treatment in COPD
may be either one of these goals or both goals together.
The continuation or termination of a specific therapy is
decided based on which goal is targeted (fig. 1).
2 If a particular pharmacotherapy is started in an effort to
achieve both goals, the decision whether to continue or
discontinue is made based on goal 2, that is the aim to
reduce future risk (exacerbations). This is because the abil-
ity or inability of any particular drug to improve lung
function or symptoms is not known to predict its ability to
reduce exacerbations of COPD.
3 The pharmacological groups of inhaled drugs and the com-
pounds used in the pharmacotherapy of COPD are shown
in table 3.
4 The effects of several pharmacotherapies of COPD as well
as the effects of smoking cessation and exercise on differ-
ent end-points and goals in the treatment of COPD are
shown in table 4.
5 The pharmacotherapy of COPD is based on the individual
patient phenotype, on the level of symptoms and the risk
of exacerbations. These are described in the section
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‘COPD phenotypes and phenotype-specific pharmacotherapy
of COPD’. Grouping of patients to three different pheno-
types is shown in fig. 2.
6 Phenotype and phenotype-based pharmacotherapy (fig. 2)
should be evaluated at every visit to health care as the
phenotype may change when the disease progresses (espe-
cially with regard to an increase in exacerbation risk)
[36].
7 So far, no pharmacotherapy has definitively been shown to
slow down disease progression (annual FEV1 decline) or
reduce mortality [37–43], even though preliminary findings
suggesting such effects have been published.
8 The principles for combining different drugs in the treat-
ment of COPD are shown in table 5.
9 A short-acting bronchodilator to be used on as-needed
basis is considered beneficial for most patients treated with
long-acting bronchodilators or combination therapy includ-
ing long-acting bronchodilators.
Bronchodilators.
Drugs that relieve bronchial obstruction by reducing bronchial
smooth muscle contraction are called bronchodilators. Usually,
they improve spirometric values reflecting obstruction such as
FEV1. These compounds generally improve also emptying of
the lungs and reduce air trapping (dynamic hyperinflation/
restriction) both at rest and during exercise [44]. These effects
cannot be predicted based on the ability of the particular com-
pound to improve FEV1 [45–48]. The dose–response effect of
all bronchodilators at the currently used doses is relatively flat,
which means that a small increase (e.g. doubling) in the dose is
not expected to produce a vast increase in the bronchodilatory
action [49–51]. The adverse effects are generally dose-related.
Increase in the dose of short-acting inhaled b2-agonist and anti-
cholinergic, especially when given nebulized, may relieve sub-
jective dyspnoea in acute setting during an exacerbation of
COPD but may not help as a long-term therapy [52,53].
Bronchodilators can be divided into short acting (duration
of bronchodilatory effect generally 3–6 hr) and long acting
(duration of bronchodilatory effect generally 12–24 hr). There
are two different classes of bronchodilators that have basically
similar bronchodilatory action in the treatment of COPD but
different mechanism of action. These pharmacological classes
are b2-agonists and muscarinic receptor (M1, M2 and M3)
antagonists (termed anticholinergics) [54,55]. Both of these
pharmacological classes contain short-acting and long-acting
preparations. Bronchodilators are usually administered on
either as-needed (usually short-acting preparations) or regu-
larly (usually long-acting preparations) to treat or prevent the
occurrence of symptoms.
A short-acting bronchodilator to be used as-needed is con-
sidered beneficial for most patients even though they were
treated with long-acting bronchodilators or combination ther-
apy including long-acting bronchodilators. Instead, the use of
regular, high-dose (nebulized, etc.), short-acting bronchodilator
or their combination in patients treated with long-acting bron-
chodilators is not evidence based [3] and should only be
reserved to treatment of the most difficult cases. In such a sit-
uation, the need for long-acting bronchodilators should be
carefully evaluated as well as the ability of the patient to prop-
erly inhale them.
Short- and long-acting b2-agonists (SABA, LABA).
The main beneficial effect of b2-agonists is the reduction of
bronchial smooth muscle contraction that leads to relief of
bronchial obstruction. The duration of the effect of short-act-
ing b2-agonists is usually 3–6 hr. Short-acting b2-agonist used
either as-needed or regularly reduce symptoms of COPD and
improve lung function [56]. The effect of long-acting b2-
Long-term pharmacological treatment of COPD has two separate aims, but same medication may help
in achieving therapeutic benefit in both aims.
Aim 1: Controlling symptoms
Bronchodilation; reduction of symptoms
either short-term or long-term
• SABA: fenoterol, salbutamol, terbutaline
• SAMA: ipratropium
• LABA: formoterol, indacaterol, olodaterol, salmeterol
• LAMA: aclidinium, glycopyrronium, tiotropium,
umeclidinium
• Teophylline (?)
Aim 2: Reducing future risk
Preventing future exacerbations of COPD
• LAMA: Tiotropium, aclidinium, glycopyrronium,
umeclidinium
• ICS + LABA
• LABA: salmeterol, formoterol, olodaterol,
indacaterol
• LABA + LAMA
• Roflumilast
How to evaluate the effectiveness of the medication and
how to decide whether to stop or continue medication?
Evaluate first whether the given medication is used to achieve aim 1 or aim 2.
If the given drug is used to achieve both aims, the decision whether or not to continue
is made based on the criteria shown for the aim 2.
Aim 1: One or more of the following findings in
the absence of severe adverse events support
the continuation of the given medication
• Reduction in daily symptoms
• symptom assessment e.g. by CAT®-test
• Improvement in exercise tolerance
• Improvement in objective lung function
measurements (e.g. FEV1, FVC or PEF; however,
this is not a prerequisite to continue medication)
Aim 2: One or more of the following findings
supports stopping the medication:
• Appearance of a severe adverse effect
• Appearance of a mild to moderate adverse effect
that is frequent and/or affects the quality of life (e.g.
repeating episodes of candidiasis or diarrhoea) and
disappears after stopping the medication
• Of note! Lack of improvement in symptoms or
lung function is not a reason to stop medication!
Fig. 1. Aims of the pharmacotherapy of chronic obstructive pulmonary disease (COPD) and principles for the evaluation whether to continue or
discontinue the current medication.
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agonists lasts 12 hr (formoterol or salmeterol) or 24 hr (ind-
acaterol, olodaterol or vilanterol). The bronchodilatory action
of formoterol/indacaterol/olodaterol/vilanterol starts sooner
(within 5 min.) than that of salmeterol (within 20–30 min.).
Indacaterol improves lung function (e.g. FEV1), reduces dysp-
noea during exercise and improves the quality of life, but the
evidence on the reduction of COPD exacerbations is still preli-
minary [57–60]. The efficacy of indacaterol, olodaterol or vi-
lanterol, when measured using FEV1 or quality of life, is at
least as good as that of formoterol or salmeterol [58,61–63] or
the long-acting anticholinergic tiotropium [58,61,64].
Generally, b2-agonists are well tolerated. Typical adverse
effects include tremor, tachycardia and palpitations that have
been reported in <1% of patients. Headache, muscular
cramps and an increase in the blood glucose and a decrease
in potassium levels are possible, even though these events
occur almost as often in patients treated with placebo [65].
It has been suggested that activation of heart b2-receptors
by b2-agonists might induce ischaemia, cardiac insufficiency
and arrhythmias or increase the risk of sudden death. How-
ever, in controlled clinical studies recruiting patients with
COPD, there is no indication for the increase of arrhythmias
or cardiac deaths [65] or overall mortality [66] by b2-agon-
ists. Based on a case–control study [67], an increase in the
risk of severe arrhythmias is possible. Thus, the benefits of
using long-acting b2-agonist in patients with severe cardiac
disease should be carefully considered.
The use of long-acting b2-agonists in the treatment of
asthma in the absence of simultaneous ICS is prohibited [7]
because there is evidence that treatment of asthma with long-
acting b2-agonists in the absence of ICS increases mortality
due to asthma [68]. In contrast, in the treatment of COPD, a
long-acting b2-agonist can be used as the sole therapy as it
does not increase mortality in COPD according to the studies
published [65,66]. According to some cohort studies, use of
long-acting b2-agonist may even reduce the mortality of
patients with COPD [69,70].
Short- and long-acting anticholinergics (SAMA, LAMA).
Anticholinergic compounds block muscarinic receptors
(M1, M2 and M3), thus antagonizing acetylcholine-induced
bronchial smooth muscle contraction. The duration of the
effect of short-acting anticholinergic (ipratropium) is usually
somewhat longer (even up to 8 hr) than that of the short-act-
ing b2-agonists (3–6 hr), but starts more slowly [54,55]. The
effect of long-acting anticholinergics lasts either 12 hr (aclidi-
nium) or approximately 24 hr (glycopyrronium, tiotropium or
umeclidinium). Of these, tiotropium has been most extensively
studied and used. The bronchodilatory action of aclidinium
and glycopyrronium starts sooner than that of tiotropium.
Tiotropium improves lung function and quality of life and
reduces symptoms and exacerbations of COPD (A) [71]. In
contrast, tiotropium does not affect the progression of the dis-
ease as judged by the annual decline in FEV1 [72]. Tiotropium
may be more effective than salmeterol in reducing exacerba-
tions of COPD [73]. Both aclidinium and glycopyrronium
have been shown to induce bronchodilation, improve lung
function and quality of life and reduce the need for rescue
medication [74,75], and their efficacy roughly equals to that
of tiotropium. Aclidinium, glycopyrronium and umeclidinium
have been shown to reduce COPD exacerbations in studies
lasting up to 1 year [76–78], but long-term studies lasting
more than 1 year, similar to those made with tiotropium
[72,73], are still lacking.
Inhaled anticholinergics are generally well tolerated, and
adverse effects occur relatively seldom. Typical adverse
effects, such as dry mouth, blurred vision, throat irritation, rhi-
nitis, constipation and nausea, are due to blocking of musca-
rinic receptors. Other possible adverse effects include also
arrhythmias, urinary retention/obstruction, elevated intraocular
pressure and acute or worsening of narrow-angle glaucoma
[79].
The short-acting anticholinergic ipratropium has been sus-
pected to induce cardiac adverse effects [79]. With the long-
acting anticholinergics, no similar increase in cardiac adverse
effects has been reported with certainty [79]. The 4-year-long
UPLIFT trial reported that there were statistically significantly
less cardiac adverse effects and the total mortality was numeri-
cally, although not statistically, lower in patients treated with
tiotropium [72].
Recently, it has been proposed that dosing of tiotropium
with Respimat device (Boehringer Ingelheim, Ingelheim,
Table 3.
Pharmacological compounds used in the therapy of chronic obstructive
pulmonary disease.
Pharmacological group and
its abbreviation
Compounds belonging to
the group
Short-acting b2-agonists Salbutamol
Terbutaline
Long-acting b2-agonist (LABA) Formoterol
Indacaterol
Olodaterol
Salmeterol
Vilanterol
Short-acting anticholinergic Ipratropium
Long-acting anticholinergic
(LAMA)
Aclidinium
Glycopyrronium
Tiotropium
Umeclidinium
Inhaled glucocorticoids (ICS) Beclomethasone dipropionate
Budesonide
Ciclesonide
Fluticasone propionate
Fluticasone furoate
Mometasone
Fixed combination of inhaled
glucocorticoid and long-acting
b2-agonist (ICS + LABA)
Budesonide–formoterol
Beclomethasone dipropionate–
formoterol
Fluticasone propionate–salmeterol
Fluticasone furoate–vilanterol
Fixed combination of long-acting
anticholinergic and long-acting
b2-agonist (LAMA + LABA)
Glycopyrronium–indacaterol
Umeclidinium–vilanterol
Phosphodiesterase 4 (PDE4)
inhibitors
Roflumilast
Others Theophylline
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Table 4.
Effects of smoking cessation, exercise and various pharmacotherapies in the treatment of chronic obstructive pulmonary disease (COPD).
Smoking
cessation Exercise
Short-acting
bronchodilator
(b2-agonist or
anticholinergic)
Long-acting
b2-agonist
Long-acting
anticholinergic
Addition of
inhaled glucocorticoid
in severe COPD1
Roflumilast
in severe COPD
Symptoms + + + + + (+) 
Obstruction +  + + + (+) (+)
Exacerbations + +  + + + +
Disease progression
(annual FEV1 decline)
+ ?    (+) ?
Mortality + +    (+) ?
+: definite beneficial effect; (+): small or possible beneficial effect; : no effect; ?: no evidence.
1In practice means terminating long-acting b2-agonist and prescribing a combination product containing both inhaled glucocorticoid and long-acting
b2-agonist.
Is it
asthma-COPD
overlap?
Low
exacerbation risk
Asthma-COPD overlap
syndrome (ACOS)
High
exacerbation risk
When should
COPD be
suspected?
• Post-bronchodilataon FEV1/FVC < 0.7 in spirometry
• Risk factors: smoking history > 10 pack-years (somemes long-term heavy exposure to dust or alpha-1-
antrypsin deﬁciency)
• Symptoms typical to COPD: cough, sputum producon, dyspnoea (in exercise), wheezing
– Of note: some of the paents are asymptomac
Is it un-treated
asthma?
• If obstrucon can be totally reversed (FEV1/FVC ≥ 0.7) with treatment (inhaled glucocorcoid, long-acng
β2-agonist can be added) is not COPD
• Consider whether the criteria for asthma is met
Diagnose COPD if • Despite possible therapy, obstrucon (post-bronchodilator FEV1/FVC < 0.7) remains
• There is idenﬁable risk-factor for COPD (smoking > 10 pack-years, heavy long-term dust exposure or
alpha-1-antrypsin deﬁciency)
• Disease presentaon conforms COPD (e.g. not untreated asthma)
• The paent may have both COPD and asthma (see below)
Treatment for all
paents with
COPD
• Smoking cessaon
• Frequent exercise (consider special pulmonary rehabilitaon)
• Vaccinaon: inﬂuenza (yearly), pneumococcal
Phenotype-
speciﬁc therapy
• Is it asthma-COPD overlap syndrome (ACOS)?
• What is the exacerbaon risk?
Has there been ≥ 2 COPD exacerbations or
one leading to hospitalization during last year
or is FEV1 < 50 % predicted ?
see criteria
Drug therapy is a combination
from COPD and asthma
guidelines
Notice both diseases!
Generally, medication includes
at least the following
• ICS + LABA or
• ICS + LABA + LAMA
Try these, combination possible
Consider risks and benefits individually
• LAMA
• ICS + LABA
• LAMA + LABA
• Roflumilast (if frequent
exacerbations, chronic bronchitis
and FEV1 < 50 % predicted)
Less symptoms (CAT® score <10)
• SABA and/or SAMA as needed
More symptoms (CAT® score ≥10)
• Daily LABA and/or LAMA
• Consider alternative diagnosis,
especially cardiac disease
• (Theophylline)
Criteria for asthma-COPD
overlap syndrome
2 main criteria, or
1 main and 2 additional criteria
Main criteria
• Significant bronchodilatory
response (FEV1 > 15 % and > 400
ml)
• Sputum eosinophilia or elevated
(>50 ppb) exhaled NO
• Previous asthma symptoms
(starting age at < 40 y)
Additional criteria
• Elevated total IgE
• Atopy
• Repeated significant
bronchodilatory response (FEV1 >
12 % and > 200 ml)
• PEF-follow-up typical to asthma
Consider referral to
respiratory
specialisf
• There are diagnosc problems
• There are therapeuc problems
• The ability to work is in queson
• Long-term oxygen therapy is considered (SaO2 < 90 % at rest and stopped smoking)
Fig. 2. The principles of diagnostics and phenotype-specific therapy of chronic obstructive pulmonary disease (COPD). Of note, the current indica-
tion for the use of different fixed combinations of inhaled glucocorticoid ICS and long-acting b2-agonist (LABA) in COPD is frequent exacerba-
tions despite the use of appropriate bronchodilator therapy, but the FEV1 ranges from <50% predicted (budesonide–formoterol, beclomethasone
dipropionate–formoterol) to <60% predicted (fluticasone propionate–salmeterol) and to <70% predicted (fluticasone furoate–vilanterol).
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Germany) would cause more deaths than its dosing with
Handihaler device (Boehringer Ingelheim, Ingelheim,
Germany) [79]. However, a direct comparison of the two
devices for a mean of 2.3 years indicated that there were no
differences in mortality, serious cardiac adverse effects or
exacerbations of COPD [80].
Combination bronchodilator therapy.
Bronchodilators with a different mechanism or duration of
action can be relatively freely combined (table 5), and the
combination may have a better bronchodilatory effect [81].
For example, combination of a short-acting anticholinergic
with a short- or long-acting b2-agonist improves FEV1 better
than any of the single agents [81,82]. Short- or long-acting b2-
agonist can be combined with a long-acting anticholinergic if
a single agent is not improving symptoms enough [81–83].
The combination of tiotropium and a long-acting b2-agonist
apparently improves the lung function and quality of life
somewhat better than tiotropium alone (B) [83]. The use of
short- and long-acting anticholinergic compounds together is
not recommended. Even though this combination may improve
results of lung function tests better than the single agents, it
will increase the risk of adverse effects such as urinary reten-
tion [84]. Combination of a short-acting b2-agonist with a
long-acting anticholinergic will result in at least as good a
response in lung function parameters without a risk of anticho-
linergic adverse effects. Thus, if a patient is using a long-act-
ing anticholinergic, the rescue medication should be a short-
acting b2-agonist [84].
After the finalization of the Finnish guideline [2,8,9], two
fixed-dose combinations of a long-acting b2-agonist and a
long-acting anticholinergic have been approved to be used in
the treatment of COPD, namely indacaterol–glycopyrronium
and vilanterol–umeclidinium. In most studies, both of these
fixed combinations have been shown to improve lung function
(e.g. trough FEV1) and health status and to reduce dyspnoea
better than the single monocomponents alone in patients with
moderate-to-severe COPD with no apparent safety concerns
[64,85–89]. In addition, the fixed-dose combination of indaca-
terol–glycopyrronium has been reported to reduce moderate-
to-severe COPD exacerbations better than glycopyrronium
alone [90].
Inhaled glucocorticoids.
In the treatment of asthma, the therapeutic and adverse effects
of ICS depend on the dose used [91]. Instead, in the treatment
of COPD, the dose dependency of the therapeutic and adverse
effects of ICS is not known [92,93]. In long-term trials, only
moderate and high doses of ICS have been used [92,93]. Reg-
ular long-term (>6 months) therapy with ICS in COPD
reduces exacerbations and slows down the decline in the qual-
ity of life [93]. Generally, patients with mild disease and with-
out previous exacerbation history do not benefit from ICS
[3,93]. The response to ICS in COPD cannot be foretold from
the response to oral glucocorticoids or by measuring hyper-
reactivity or response to bronchodilators (bronchodilator test
in spirometry) [93]. Discontinuation of ICS may precipitate
exacerbation of the disease in some patients with COPD [94]
but may be safely performed in others to decrease risk of
long-term adverse effects [95]. ICS alone do not affect mortal-
ity due to COPD or the rate of decline of lung function
(annual FEV1 decline) [93]. Adverse effects include candida
infection in the mouth and hoarseness. Also, there is evidence
that use of ICS is associated with an increased risk of pneu-
monia [93] and fractures [96]. Initiation of ICS therapy has
been associated with increased risk of diabetes in respiratory
Table 5.
The principles of combining drugs used to treat chronic obstructive pulmonary disease (COPD). The general rule of drug therapy of COPD is that
two drugs belonging to the same group or having similar mechanism of action should not be combined. The exception to this rule is the simulta-
neous use of short- and long-acting b2-agonists that is allowed and often is meaningful.
If there is a clinical indication to combine drugs from the following groups, there is no pharmacological reason to prevent the combination. To a
single patient, only one compound or product can be selected from the following groups of drugs
Short-acting bronchodilators (‘reliever medication’)1
Short-acting b2-agonist (fenoterol, salbutamol, terbutaline)
Short-acting anticholinergic (ipratropium)2
Long-acting bronchodilators1
Long-acting b2-agonist (formoterol, indacaterol, olodaterol, salmeterol, vilanterol)
Long-acting anticholinergic (aclidinium, glycopyrronium, tiotropium, umeclidinium)2
Glucocorticoids
Inhaled glucocorticoids (beclomethasone, budesonide, fluticasone, mometasone, ciclesonide)
Oral medications
Phosphodiesterase 4 inhibitors (roflumilast)3
Theophylline3
1The duration of action of the compound does not prevent the combination. For example, two long-acting bronchodilators can be combined as long
as they have a different mechanism of action (i.e. tiotropium and indacaterol can be combined). Similarly, short-acting anticholinergic (ipratropium)
can be combined with short-acting b2-agonist (e.g. salbutamol). Instead, two different b2-agonists with similar duration of action should not be
combined (e.g. indacaterol should not be combined with formoterol or salmeterol). Use of a short-acting b2-agonist as needed with a regular long-
acting b2-agonist is acceptable.
2Use of short-acting anticholinergic (ipratropium) with long-acting anticholinergic is not recommended.
3Phosphodiesterase 4 inhibitors and theophylline should not be combined because of the risk of adverse effects.
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patients in general in a registry-based study [97], but in a ret-
rospective analysis of shorter placebo-controlled, double-blind
studies in patients with asthma or COPD, it has not been con-
firmed [98].
Long-term therapy with ICS in addition to other therapy is
recommended only for patients with ACOS or patients with a
high risk of exacerbations of COPD, that is with severe or
very severe obstruction in spirometry (table 2) and a history
of frequent exacerbations (fig. 2) [99]. The use of ICS as the
sole long-term therapy of COPD should be avoided as the
combination of inhaled glucocorticoid with long-acting b2-
agonist is more efficient in reducing exacerbations of the dis-
ease and possibly better in reducing mortality and improving
lung function and quality of life [100]. The use of ICS outside
the current indications is not recommended as long-term ther-
apy with these may increase the risk of pneumonia [92,93],
osteoporosis and fractures [96].
Combination of inhaled glucocorticoid and long-acting
b2-agonist.
In COPD, the current indication for the use of different fixed
combinations of ICS and long-acting b2-agonist is frequent
exacerbations despite the use of appropriate bronchodilator
therapy, but the accepted FEV1 ranges from <50% predicted
(budesonide–formoterol, beclomethasone dipropionate–formo-
terol) to <60% predicted (fluticasone propionate–salmeterol)
and to <70% predicted (fluticasone furoate–vilanterol). The
combination of inhaled glucocorticoid and a long-acting b2-
agonist reduces exacerbations and improves lung function and
quality of life in COPD (A) [101]. In addition, combination of
inhaled glucocorticoid and a long-acting b2-agonist is better
than placebo or any of its components in improving lung func-
tion and health status and reducing exacerbations in patients
with COPD [100,102–105]. In a large, prospective 3-year trial
with a combination of inhaled glucocorticoid and a long-acting
b2-agonist, there was no statistically significant effect on mor-
tality [106]. However, in a subsequent meta-analysis, it was
found that a combination of inhaled glucocorticoid and a
long-acting b2-agonist may reduce mortality (number needed
to treat NNT = 36 to prevent one extra death; 95% CI 21;
258) [104].
The use of a combination of an inhaled glucocorticoid and
a long-acting b2-agonist is associated with adverse effects typ-
ical for both its components. The increased risk of pneumonia
is considered as the most significant in patients with COPD
[99,104]. At present, it remains uncertain to what extent
increased risk of pneumonia is associated with other ICS or
combinations of ICS and long-acting b2-agonists, but a combi-
nation of inhaled fluticasone propionate and salmeterol may
cause a higher risk [107–110].
Even though COPD is largely an under-diagnosed and
under-treated disease [3], over-treatment of mild-to-moderate
COPD (spirometric GOLD classification; table 2) with combi-
nations of ICS and long-acting b2-agonists was recently
reported [111]. This cannot be recommended and leads to
unnecessary adverse effects and costs [111].
Addition of a combination of an inhaled glucocorticoid and
a long-acting b2-agonist to tiotropium therapy has been
reported to improve lung function and the quality of life, and
it may even further reduce the occurrence of exacerbations,
particularly severe exacerbations [112–115], but more and
longer studies are needed. Preliminary evidence suggests that
the triple therapy is cost-effective in Finland and other Scandi-
navian countries [116].
Roflumilast.
Roflumilast inhibits the inflammatory reaction associated with
COPD by inhibiting enzyme phosphodiesterase 4 (PDE4) and
by increasing intracellular cyclic adenosine monophosphate
(cAMP) content [57]. Roflumilast is given orally as one tablet
daily. It is not a bronchodilator and cannot be used to relieve
acute bronchial obstruction, even though during long-term
therapy in patients already on salmeterol or tiotropium, roflu-
milast further increases FEV1 by 50–80 ml [57,117–119].
Roflumilast reduces exacerbations of COPD and improves
lung function, but it also has significant adverse effects (A)
[117]. Roflumilast reduces moderate (requiring systemic
glucocorticoids) and severe (leading to hospitalization or
death) exacerbations in patients with COPD who have severe
COPD (FEV1 < 50% predicted), chronic bronchitis and fre-
quent exacerbations despite long-acting bronchodilators
[57,117,118]. In contrast, the effects on the quality of life and
symptoms are less pronounced [57,117].
Typical adverse effects of roflumilast are gastrointestinal
complaints and headache. Weight loss is also common, and
the weight should be followed [117,118].
Other pharmacological treatments used for long-term therapy.
Oral glucocorticoids. A treatment trial with oral glucocort-
icoids is not recommended in patients with COPD to identify
those who will respond to ICS. A response to oral
glucocorticoids has not been shown to predict the response to
other treatments [23–27]. However, this does not prevent us from
treating exacerbations with a course of oral steroids or trying a
course of oral steroids in a patient with difficult symptoms.
Even though a high dose (equalling ≥30 mg oral predniso-
lone per day) of oral glucocorticoids improves lung function
in the short run, there is no evidence of long-term benefits of
oral glucocorticoids at low or moderate to high doses [120].
In contrast, there is evidence to suggest increased risk of
adverse effects [120]. Thus, long-term therapy of COPD with
oral glucocorticoids should be avoided as it may even worsen
the long-term outcome of the patient [121]. Oral glucocortic-
oids have several significant adverse effects – one of the most
important in the treatment of COPD being steroid myopathy
which presents with symptoms such as muscular weakness,
impaired physical activity and respiratory insufficiency in
patients with very severe COPD [122]. Regular long-term oral
glucocorticoid therapy has several well-known adverse effects,
and thus, it is easy to understand that there exist no studies on
its use in the treatment of stable COPD [3].
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Theophylline. The exact mechanism of action of theophylline
remains unknown, but it has both bronchodilatory and anti-
inflammatory effects. The pharmacokinetics of theophylline
varies between individuals and is prone to drug–drug
interactions [123,124]. For this reason, its blood concentrations
need to be followed and the dosing needs to be adjusted. The
duration of effect in COPD is not known even in the case of
currently used slow-release preparations [3].
The reports on the effects of theophylline in COPD are con-
troversial. Theophylline apparently improves lung function in
COPD, but the risk of adverse effects increases (B) [125–
127]. Theophylline may improve the function of inspiratory
muscles [123]. The effect of theophylline on lung function
and symptoms in COPD is less than that of long-acting b2-ag-
onists formoterol and salmeterol [126,128]. Addition of the-
ophylline to salmeterol improved FEV1 and reduced dyspnoea
better than salmeterol alone [128]. Small dose of theophylline
(100 mg twice daily) reduced COPD exacerbations statistically
significantly, but did not improve lung function as judged by
post-bronchodilator spirometry [127].
The therapeutic concentration range of theophylline is nar-
row, and widespread toxicity is easily a problem [3,123,124].
The most usual adverse effects include gastric irritation, nau-
sea, vomiting, diarrhoea, increased diuresis and signs of stimu-
lation of central nervous (headache, nervousness, anxiety and
agitation) and cardiac electrical (arrhythmias, specially tachy-
cardia) systems [54,55,123,124,129]. For this reason, the use
of theophylline has diminished, and it is recommended for the
treatment of COPD only as an additional therapy to patients
with severe symptoms.
Antimicrobial compounds.
A recent meta-analysis reported that regular use of macrolides
(erythromycin, clarithromycin and azithromycin) in six studies
(lasting 3–12 months) resulted in a 37% decrease in COPD
exacerbations as compared with placebo. In addition, hospital-
ization was reduced by 21%, and the share of patients suffer-
ing from exacerbations was reduced by 68% but at the
expense of increased risk of hearing loss [130,131]. However,
a widespread use of macrolides is restrained by the fear of
increased resistance of bacteria to macrolides [130].
Compounds affecting sputum production or consistency
(mucolytics).
The group of mucolytic drugs consists of several compounds
with varied mechanisms of actions, part of which remain
unknown [54,55]. The regular use of mucolytics in COPD has
been a subject of several studies with conflicting results
[3,132].
Mucolytics apparently reduce COPD exacerbations, but they
do not improve lung function or induce significant adverse
effects (B) [132].
Choice of the inhaler.
A significant proportion of the patients commit errors in using
their inhalers [133], so the correct use should be taught and con-
trolled when starting the treatment and also at control visits.
The use of dry powder inhaler (DPI) does not require co-
ordination of actuating the device and inhalation, but sufficient
inspiratory strength is needed to create high enough inspira-
tory flow.
The use of pressurized, metered dose inhaler (pMDI) does
not require high inspiratory flow, but the patient needs to be
able to co-ordinate the actuation of the inhaler at the begin-
ning of inhalation.
The use of valved holding chambers or spacer devices alle-
viates the problem with co-ordination, and they diminish oral
and pharyngeal deposition when suspension aerosols are used
[134].
Inspiratory flow is not always sufficient for the use of DPI
in individuals with a more severe COPD [135]. A pMDI
should then be used, and, if needed, holding chamber with or
without mask and assistance from a caregiver can also be
used. The basic principles of choosing a correct inhaler are
shown in table 6 [136].
COPD Phenotypes and Phenotype-Specific
Pharmacotherapy of COPD
1 The pharmacotherapy of COPD is based on the individ-
ual patient phenotype, on the level of symptoms and the
risk of exacerbations. Grouping of patients to three differ-
ent phenotypes is shown in fig. 2.
Table 6.
Choosing a suitable inhaler.
Choosing a suitable inhaler
1. Assess the patients’ ability to co-ordinate actuation of the pMDI and inhalation
2. Assess the patients’ ability to create sufficient inspiratory flow for using DPI
Good co-ordination Poor co-ordination
Inspiratory flow > 30 l/min. Inspiratory flow < 30 l/min. Inspiratory flow > 30 l/min. Inspiratory flow < 30 l/min.
DPI
pMDI
SMI
BA-MDI
(nebulizer)
pMDI
SMI
(nebulizer)
DPI
BA-MDI
pMDI + spacer
(SMI)
(nebulizer)
pMDI + spacer
(SMI)
(nebulizer)
DPI, dry powder inhaler; pMDI, pressurized, metered dose inhaler; SMI, soft mist inhaler; BA-MDI, breath-actuated metered dose inhaler.
Modified from reference [136].
© 2014 The Authors. Basic & Clinical Pharmacology & Toxicology published by John Wiley & Sons Ltd on behalf of Nordic Association for the Publication of BCPT
(former Nordic Pharmacological Society).
300 HANNU KANKAANRANTA ET AL. MiniReview
2 Phenotype and phenotype-based pharmacotherapy (fig. 2)
should be evaluated at every health care visit as the pheno-
type may change when the disease progresses (especially
with regard to exacerbation risk) [36].
Low risk of exacerbations.
A phenotype of COPD that is characterized by a low risk of
exacerbations based on infrequent previous exacerbations and
relatively good lung function (i.e. FEV1 ≥ 50% predicted) and
the patient is not presenting with the typical features of ACOS
(fig. 2). The patients are divided into two groups: those with
less symptoms (CAT score < 10 or mMRC score < 2) or
those with more symptoms (CAT score ≥ 10 or mMRC
score ≥ 2 points) and limitations of physical activity or quality
of life due to COPD.
1 In patients with less symptoms, a short-acting bronchodila-
tor, either b2-agonist or anticholinergic, is recommended.
If a single compound is not enough to control the symp-
toms, a combination of short-acting b2-agonist and anti-
cholinergic can be used, even though there is not much
evidence to support this treatment option [81].
2 If a short-acting bronchodilator is not enough to control the
symptoms or the patient is having plenty of symptoms, a
long-acting bronchodilator, either b2-agonist or anticholin-
ergic, can be used. In patients with more symptoms, long-
acting bronchodilators are more effective than short-acting
bronchodilators and thus are recommended [82,137].
3 At the moment, there is not enough evidence available to
recommend one class (b2-agonist or anticholinergic) of
long-acting bronchodilators over the other as initial therapy
in COPD [3]. The choice of a long-acting bronchodilator
for long-term use should be made based on the symptom-
atic benefit experienced by the patient.
4 A combination of tiotropium and a long-acting b2-agonist
apparently improves the quality of life and lung function
better than tiotropium alone (B) [58,83].
5 A combination product of long-acting bronchodilators
(glycopyrronium and indacaterol) apparently improves spi-
rometric lung function test results and quality of life better
than any of its components alone (B) [85,90].
6 Theophylline can be combined to the bronchodilators
described above, but the evidence to recommend its use
alone or as a combination is limited. Theophylline appar-
ently improves lung function in COPD, but the risk of
adverse effects increases (B) [125–127].
7 If the patient is experiencing more symptoms and his/her
lung function is only moderately reduced (i.e. FEV1 is
≥50% predicted), then consider the possibility of additional
or alternative diagnosis, especially cardiac disease or lung
cancer [36,138].
High risk of exacerbations.
A phenotype that is characterized by a high risk of exacerba-
tions either based on previous exacerbation history or severe
to very severe airflow limitation (i.e. FEV1 is <50% predicted)
and the patient is not presenting with the typical features of
ACOS. The main aim of the pharmacotherapy in this patient
group in addition to relieving symptoms is to prevent and to
reduce the severity of exacerbations of COPD.
The recommended first choice of pharmacotherapy is as fol-
lows:
1 A long-acting anticholinergic or a combination of inhaled
glucocorticoid and long-acting b2-agonist:
 The combination of inhaled glucocorticoid and a long-
acting b2-agonist reduces exacerbations and improves lung
function and quality of life in COPD (A) [101].
 Tiotropium improves lung function and quality of life and
reduces symptoms and exacerbations of COPD (A) [71].
 There is not enough evidence available to recommend
one of these options over the other as initial therapy in
high exacerbation risk phenotype of COPD [139].
Other treatment options:
1 Combination of two long-acting bronchodilators:
 Long-acting anticholinergics [71] and long-acting b2-ag-
onists [140] reduce exacerbations of COPD, even though
studies evaluating the effects of a combination of long-act-
ing bronchodilators administered via separate inhalers are
still scarce [58,83].
 A combination product of long-acting bronchodilators
(glycopyrronium and indacaterol) apparently improves spi-
rometric lung function test results and quality of life better
than its components alone (B) [85,90] and may reduce
COPD exacerbations better than long-acting anticholinergic
alone [90] and thus may be used.
2 Roflumilast:
 If the patient is having severe-to-very severe COPD
(FEV1 < 50% predicted), chronic bronchitis and frequent
exacerbations despite long-acting bronchodilators, the phar-
macotherapy may include also roflumilast.
 Roflumilast reduces exacerbations of COPD and
improves lung function, but it also has significant adverse
effects (A) [117].
3 Triple therapy:
 If the patient is having more symptoms in addition to
exacerbations, a combination of three agents (i.e. an
inhaled glucocorticoid, a long-acting b2-agonist and a long-
acting anticholinergic) may be used. The evidence of the
usefulness of this triple combination is mainly based on
short trials [112–115].
4 Inhaled glucocorticoid and long-acting anticholinergic:
 This is not a therapy based on strong evidence, but in
theory it is considered sensible. The reason for the absence
of evidence most probably is due to the lack of interest by
the pharmaceutical industry rather than not being a rational
combination [3].
5 Long-acting b2-agonist:
 Long-acting b2-agonist (formoterol or salmeterol) reduces
exacerbations and hospitalizations due to COPD and
improves lung function (A) [106,140,141]. Both com-
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pounds also improve significantly the quality of life and
reduce the need for rescue medication, but do not reduce
mortality due to COPD or the annual decline in FEV1
[106,140].
 Long-acting b2-agonist as the sole therapy of high-risk
phenotype of COPD is not, however, recommended
because these studies were not carried out in patients prone
to COPD exacerbations [140] and because there is solid
evidence of the efficacy of both the long-acting anticholin-
ergic [71] and the combination of inhaled glucocorticoid
and long-acting b2-agonist [104] in this indication.
6 Theophylline:
 Theophylline can be combined with inhaled glucocorti-
coid and/or long-acting bronchodilators, but the evidence
of its efficacy in reducing COPD exacerbations as part of a
combination therapy or alone is very limited [127]
7 Antibiotics
 Regular use of macrolides (erythromycin, clarithromycin
and azithromycin) reduces COPD exacerbations [130], but
widespread use of macrolides is restrained by the fear of
increased resistance of bacteria to macrolides. For this rea-
son, long-term therapy with antimicrobial compounds
should be restricted to patients who suffer from repeated
exacerbations leading to hospitalization despite adequate
pharmacotherapy of COPD [92]. The decision to start and
to follow up on this kind of therapy always necessitates
specialist consultation.
8 Compounds affecting sputum production or consistency
(mucolytics)
 Mucolytics apparently reduce COPD exacerbations, but
they do not improve lung function or induce significant
adverse effects (B) [132].
 The long-term use of mucolytics in the routine therapy of
COPD is not recommended. However, some patients pre-
senting with severe over-production of viscous mucus may
benefit from them [132]. At the moment, no clear evidence
exists to guide the use of mucolytics in COPD (i.e. which
compound, to which kind of patients and for how long).
Asthma–COPD overlap syndrome.
1 This is a phenotype of COPD in which there are features
that comply both with asthma and with COPD (fig. 2).
Patients belonging to this phenotype have been usually
excluded from studies evaluating the effects of drugs both
in asthma and in COPD [142–144]. Thus, evidence-based
recommendation of treatment cannot be given. Further-
more, there exist no generally accepted criteria for this
condition [6,142].
2 In patients fulfilling the criteria for both asthma and COPD
and who were using ICS, addition of tiotropium improved
lung function test results and reduced the need for rescue
medication [145].
3 The treatment should cover both diseases, and, generally,
the therapy includes at least ICS combined with long-act-
ing bronchodilator (b2-agonist or anticholinergic or both)
(the reader is strongly advised to familiarize him-/herself
also with the Asthma guidelines) [6,7].
Conclusion
Optimal therapy of patients with COPD requires a tailored
and multidisciplinary approach focusing on the symptoms and
the individual future risk of the patient [3,4,146,147]. In addi-
tion, the personal needs and wishes should be taken into
account [3–5,146]. The current guideline emphasizes early
diagnosis with structured evaluation of the phenotype of each
patient. The therapy should be started early in the course of
the disease and should be phenotype-directed. The phenotype
may change during the course of the disease and should be re-
evaluated during each follow-up visit, and the pharmacother-
apy should be changed according to the changed phenotype of
the disease.
The paradigm shift in the treatment of COPD initiated by
the GOLD (Global Initiative for Chronic Obstructive Lung
Disease) report [3] offers a basis for the assessment of the
future risk of the individual patient. However, at the same
time, there is a huge lack of knowledge on the effects of phar-
macotherapies on the symptoms and risks of different pheno-
types of COPD as well as on patients with different
comorbidities. Future studies with drugs directed towards
COPD should take into consideration the different phenotypes
of the disease and include patients with comorbidities and also
follow-up for future risk end-points such as exacerbations,
hospitalizations and mortality.
We recognize several limitations of the present guideline,
and the reader may identify several deficiencies in the recom-
mendations as well as topics that remain undiscussed. Several
topics that were raised by the reviewers of the original Finnish
guideline [2,8] as well as the present version in the English
language remain untouched due to lack of evidence or due to
very conflicting evidence. In fact, much more evidence is
needed to evaluate the effectiveness of different therapies in
COPD and its specific phenotypes. However, we have very lit-
tle evidence that a specific pharmacotherapy would not help in
COPD. Thus, the reader should not consider the ‘lack of evi-
dence that a treatment works’ as a synonym for ‘evidence that
a specific treatment does not help’ in COPD [3].
Limitation of responsibility.
The practice guidelines of the Finnish Medical Society Duo-
decim are summaries on the diagnostics and effectiveness of
therapy on single diseases and are produced by experts. They
do not replace the judgement of a physician or other health-
care specialist on the best possible diagnostics and therapy of
an individual patient.
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